Publicaciones en colaboración con investigadores/as de Queen Mary University of London (194)

2024

  1. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. A systematic review and meta-analysis of the clinimetric properties of the core outcome measurement instruments for clinical effectiveness trials of nutritional and metabolic interventions in critical illness (CONCISE)

    Critical Care, Vol. 27, Núm. 1

  4. Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

    Clinical Cancer Research, Vol. 29, Núm. 21

  5. Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

  6. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  7. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  8. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  9. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    Annals of Oncology

  10. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299

  11. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176

  12. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  13. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  14. Genomic investigations of unexplained acute hepatitis in children

    Nature, Vol. 617, Núm. 7961, pp. 564-573

  15. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPE-Covid-19 Registry

    Anti-Infective Agents, Vol. 21, Núm. 2, pp. 66-78

  16. Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

    The Lancet Rheumatology, Vol. 5, Núm. 4, pp. e184-e199

  17. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  18. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

  19. Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension

    Hypertension, Vol. 80, Núm. 1, pp. 84-96